0001104659-17-041012.txt : 20170622
0001104659-17-041012.hdr.sgml : 20170622
20170622194141
ACCESSION NUMBER: 0001104659-17-041012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170620
FILED AS OF DATE: 20170622
DATE AS OF CHANGE: 20170622
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001481512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262908274
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 401-4060
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lettmann Jason
CENTRAL INDEX KEY: 0001688269
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37926
FILM NUMBER: 17926118
MAIL ADDRESS:
STREET 1: C/O RA PHARMACEUTICALS, INC.
STREET 2: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
a4.xml
4
X0306
4
2017-06-20
0
0001481512
Ra Pharmaceuticals, Inc.
RARX
0001688269
Lettmann Jason
C/O MORGENTHALER VENTURE PARTNERS IX, LP
3200 ALPINE ROAD
PORTOLA VALLEY
CA
94028
1
0
1
0
Options to Purchase Common Stock
22.37
2017-06-20
4
A
0
15000
0
A
2027-06-20
Common Stock
15000
15000
D
On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.
The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.
/s/ Benjamin Piper, Attorney-in-Fact
2017-06-22